-- Swiss stocks began the trading week on a somber note, with the Swiss Market Index down 1.45% on Monday's close, as hopes for a resolution to the war in the Middle East faded amid renewed geopolitical tensions between the US and Iran.
"The Middle East conflict escalated early this morning as the US intercepted an Iranian cargo ship trying to breach its maritime blockade, prompting Iran to vow retaliation. The prospects for a second round of negotiations remain uncertain ahead of the ceasefire's expiration on Tuesday, with Iran refusing to participate unless the blockade is lifted," Danske Bank said. "The market is likely to stay volatile this week as US and Iran will try and negotiate a deal. If oil does not start flowing through the strait soon, oil prices are likely to rise further and above USD 100/bbl again."
Meanwhile, the only agenda on the Swiss economic calendar for the week is the balance of trade data for March. Elsewhere, the April ZEW economic sentiment index for Germany and the euro area, and the UK's March inflation figures are on top of the agenda.
On the corporate front, Eli Lilly (LLY.SW) signed a definitive agreement to acquire biotechnology company Kelonia Therapeutics for up to $7 billion in cash, including an upfront payment of $3.25 billion and subsequent milestone-based payments. The transaction, which is set to complete in the second half, is expected to bolster Lilly's genetic medicine capabilities.
"Autologous CAR-T therapies have meaningfully improved outcomes for patients with various cancers, but significant manufacturing, safety, and access barriers mean that only a fraction of eligible patients actually receive them. Kelonia's in vivo platform has the potential to change that by delivering rapid, durable responses in a far simpler, off-the-shelf format," said Jacob Van Naarden, executive vice president and president of Lilly Oncology and corporate business development head. "The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia's platform."